Breast cancer is the most common cancer and also the leading cause of cancer mortality in women worldwide.
Introduction
Breast cancer, one of the most common malignancies affecting women, has attracted increasing attention by the international community and has evoked tremendous interest particularly in the medical and academic fields (Siegel et al., 2015 ).
An increasing number of studies have been performed to explore potential biomarkers that may be involved in the initiation and progression of breast cancer. Estrogen receptor (ER), progesterone receptor (PR), c-erbB-2, p53, and Ki-67 have been investigated in the conventional histopathological setting(Ding.,2017 and Parsa et al.,2016).
Survivin is an antiapoptotic protein belonging to the inhibitor of the apoptosis protein family. It is a bifunctional protein that regulates cell division and suppresses apoptosis. Survivin is highly expressed in various human malignancies, but its expression is very low or below the level of detection in normal adult tissues DNA polymorphisms with more than one variant (allele) having a frequency greater than 1 percent in a human population have been estimated to occur on the average at one in every 1000 base pairs throughout the human genome The survivin gene codifies a multifunctional protein involved in the regulation of the cell cycle and inhibition of the apoptotic pathway, and a polymorphism located in its promoter region is associated with gene regulation. Most of the polymorphic studies are confined in promoter regions among which the single nucleotide polymorphism (SNP) at -31G/C is most studied in all cancers in comparison to other polymorphic sites (Jaiswal et al.,2012 and Theodoropoulos et al.,2010). The aim of our work was to investigate -31 G/C single nucleotide polymorphism of survivin promoter in breast cancer patients.
P53-Abs were discovered 20 years ago during the course of tumorassociated antigens screening. The discovery of p53 mutation and accumulation of p53 in human tumors shed new light on the p53 humoral response. It is demonstrated that p53-Abs are found predominantly in human cancer patients with a specificity of 96%.
Such antibodies are predominantly associated with p53 gene missense mutations and p53 accumulation in the tumor, but the sensitivity of such detection is only 30%. It has been demonstrated that this immune response is due to a selfimmunization process linked to the strong immunogenicity of the p53 protein. The clinical value of these antibodies remains subject to debate, but consistent results have been observed in breast, colon, oral, and gastric cancers, in which they have been associated with high-grade tumors and poor survival. The finding of p53-Abs in the sera of individuals who are at high risk of cancer, such as exposed workers or heavy smokers, indicates that they have promising potential in the early detection of cancer(Angelopoulou et al.,1994).
Patients and methods Patients
The present study was carried out at Sohag university hospital and Sohag Cancer Institute in the period between 2016 and 2018 .100 subjects were enrolled in this study. All were women in the age between 40 and 65 (60 breast cancer cases and 40 control divided into two groups according to age: Group 1 ≤ 50 years (27.3 ± 4.87) and Group 2 > 50(24.83 ± 6.12).Clinical data were obtained from patient's files including patient age, tumor grade, tumor stage, presence of lymph nodes and metastasis,estrogen and progesterone receptors positivity and CA 15-3 level. Exclusion criteria were male breast cancer and prior chemotherapy or radiotherapy. Blood samples were collected after taking the concent. Samples were divided between EDTA (Ethylenediaminetetraacetic acid) tubes and plane tubes. EDTA tubes were preserved at -20 c until the extraction of DNA and serum was obtained from the plane tubes after centrifugation and frozen at -20 c.
Methods

DNA extraction
By the use of QIAamp DNA Mini Kits (QIAGEN, Lot No. 148046221).
Polymorphism genotyping:
To identify genetic variants in the survivin gene promoter for the screening of -31G/C polymorphism, a 329 bp region of promoter was sequenced. The survivin -31G/C polymorphism was then analyzed by polymerase chain reaction-restriction fragment containing the -31 polymorphic site was amplified using two primers; the Forward primer:5′-TCC GTA GT GAA CCT GCG G -3′ The Reverse primer: 5 ′ -TCC TCC GCT TAT TGA TAT GC -3′ Each PCR reaction was performed in the total reaction volume of 50 μL containing25 μL.My Red Taq, 2.5 μL of each primer, 15 μL genomic DNA and 5 μL grade water.The conditions of PCR: initial denaturation step at 95ºC for 7 min, followed by 35 cycles of 95ºC for 1 minute seconds as the second melting step, 54ºC for 40 seconds for primer annealing and extension at 72ºC for 35 seconds and a final extension step of 72ºC for 7 min. Digestion was performed by incubating 10 μL of PCR products that were obtained by survivin primers with 1 µl of BsiSI enzyme in a final reaction volume of 13.5µl at 37ºC for 1 hour.
The amplified PCR products and the restriction fragments were separated by electrophoresis in a 2 % agarose gel. 
ELISA kit for Detection of Anti-p53
Results
Our present study included 100 subjects. All were women in the age between 40 and 57 (60 breast cancer cases and 40 control divided into two groups according to age: Group 1 ≤ 50 years and Group 2 > 50. The age of patients ranged from(40 -57) years with a mean±SEof 48.72 ± 4.94 while the age of the controls ranged from(40 -56)years with a mean±SE of 47.55 ± 4.76. 
Discussion
The differential expression of Survivin in tumors compared with normal cells and its requirement for cancer cell survival identify it as a potential marker in cancer diagnosis as well as an attractive therapeutic target.
Survivin is an antiapoptotic protein belonging to the inhibitor of the apoptosis protein family. It is a bifunctional protein that regulates cell division and suppresses apoptosis. Survivin is highly expressed in various human malignancies, but its expression is very low or below the level of detection in normal adult tissues (Yazdani et al., 2012) .
As a member of the family of the inhibitors of apoptosis proteins (IAPs), survivin forcefully inhibits cell apoptosis and facilitates the activation and proliferation of breast cancer cells (Khan et al.,2017) . Admittedly, survivin is a downstream target of NF-κB, which in turn is activated by mTOR (Kawakami et al.,2005) . Furthermore, survivin is a potent inactivator of caspase-9 and caspase-3 and is regulated via the Akt/mTOR signaling pathway (Wilson.,2015 and Jin.,2007).
Several lines of evidence suggest that deregulation of Survivin expression occurs in cancer as a result of genetic (amplification of the Survivin locus on 17q25 in neuroblastoma), epigenetic (selective demethylation of Survivin exon 1 in ovarian cancer but not in normal ovaries), DNA polymorphisms with more than one variant (allele) having a frequency greater than 1 percent in a human population has been estimated to occur on the average at one in every 1000 base pairs throughout the human genome (Sherry et al.,1999) . Our study shows a significant difference in the prevalence of the survivin promoter polymorphism ( -31G > C) between the case and control groups, P-value (P = 0.005*). Notably, the combined prevalence of the GC and CC genotypes (GC + CC), reflecting the prevalence of the C allele, was significantly greater in the breast cancer group than in the control group (P= 0.002*) with rates of 29% and 6%, respectively. These results imply that the C allele at position -31 in the promoter region of the survivin gene increases an individual's susceptibility to breast cancer. Also, the risk of developing cancer was 4.05 times higher in patients with the GC or CC genotype (GC + CC) than in patients with the GG genotype, and this difference was statistically significant (95% CI: (1.48 -11.09).
Besides, in the breast cancer group, the GG genotype was present in 35 patients, whereas the GC + CC genotype was present in 25 patients. There were significant differences between these two groups in terms of age, hormonal therapy, stage of the tumor, metastasis and CA15-3 level.
In addition, there were no significant differences between these two groups as regards the family history, the grade of tumor, type, estrogen and progesterone receptor positivity, side, lymph node, and p53 antibodies level.
As regards the relation between age, family history and clinicopathological features of the studied breast cancer patients and survivin alleles, there were significant differences between G allele and C allele in age, progesterone receptor positivity and metastasis But, no significant differences were found as regards the hormonal therapy, family history, stage of the tumor, grade, type, estrogen receptor positivity, side, lymph node, and p53 antibodies level.
Univariate binary logistic regression analysis of genetic polymorphism among breast cancer patients revealed that the age, hormonal therapy, and metastasis could be a predictor variable. But, multiple binary logistic regression analysis results revealed that age and hormonal therapy are risk factors of genetic polymorphism among breast cancer patients. Our results are in line with a study of the role of the functional polymorphism of survivin Gene (-31G/C) and risk of breast cancer in a north Indian Population that revealed that the variant genotype/allele was found in 54.1% of the cases compared with 46.5% of controls. The combined prevalence of genotype GC+CC was significantly higher in patients compared with the control group (P = .02). Analyses of odds ratios (ORs) in the patient and control groups indicated that the presence of homozygous CC genotype was associated with increased risk for development of breast cancer (OR, 2.04; 95% confidence interval [CI], 1.07-2.98). The gene frequencies for G and C alleles were statistically different between patient and control groups (OR, 1.37; 95% CI, 1.03- In contrast to our results, a study of the association between survivin -31G/C promoter polymorphism and breast cancer in Eastern Azerbaijan, Iran, that revealed that the genotype frequencies and allele distribution of the survivin promoter -31G/C for both controls and cases were similar (  Rojhannejad et al.,2015) .
In the present study, as regards the level of p53 antibodies, there was a significant difference (p=0.025) between cases (11.67±11.96) and controls (4.65 ± 0.48). But, no significant difference in the different genotypes of breast cancer patients(p=0.83).
There was no significant difference between the age, history and clinicopathological features of the studied breast cancer patients and the level of p53 antibodies. Besides, there was no significant difference between the level of p53 antibodies among the studied breast cancer patients (p= 0.887).
Previous studies in accordance with our results, Yamamoto et al, (2012) analyzed serum anti-p53 antibody levels in 124 patients with breast cancers and 7 patients with the benign disease between April 2012 and March 2013, as well as levels of serum carcinoembryonic antigen (CEA) and cancer antigen CA15-3. They found that twenty-two of 124 patients with breast cancer had an increased concentration of anti-p53 antibodies. By distribution of clinical-stage, in stage 0-II the positive ratio of anti-p53 antibodies was significantly higher than that of CEA (p=0.03) and CA15-3 (p=0.01). There was a significant correlation between anti-p53 antibodies and family history (p=0.03). Triple-negative cancer also showed a significant correlation with anti-p53 antibodies (p=0.007). In patients with multiple and/or bilateral breast cancer, the level of anti-p53 was significantly higher than in unilateral breast cancer (62.5% vs 14.7%, p=0.004).
Also, Ahmed et al., (2011) detect antibody against p53 in the sera of eight patients (20%), the mean serum levels of p53-Abs showed a significant increase in patients (32.8±5.4pg/ml) when compared to control group (4.1±0.3pg/ml) P<0.001. Moreover the positive rate of serum p53-Abs was not related to each age, stage and histologic grade of tumor. Receiver operating characteristic (ROC) curve of p53 antibodies for optimum cut off point in predicting breast cancer shows high specificity (100) but no sensitivity (26.67). This is in line with the study done by Müller et al., (2006) for testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. The aim of this study was to determine whether anti-p53 antibodies are of clinical significance as a serological marker in the diagnosis and monitoring of malignancies. A total of 1874 serum samples from 591 patients with various types of cancer, esophageal, gastric, colorectal, pancreatic, hepatocellular, breast, and urogenital cancer, and 436 control individuals were analyzed by immunoblot for antibodies against p53.The anti-p53 antibody test was correlated with expression of conventional tumor markers, survival and the clinicopathological features of malignant disease. Anti-p53 antibodies were found in 23.4% (138/591) of the sera of patients with malignant disease (range 11.5-34%). The detection of anti-p53 serum antibodies had a specificity of 100% for malignancy (p<0.0001). The overall sensitivity of measuring established tumor markers was 62.9% (372/591). The elevation of conventional tumor markers and the presence of anti-p53 antibodies in the sera of patients with malignant disease turned out to be an independent variable (p<0.05).
A combination of established tumor markers with the anti-p53 antibody test led to an increase in diagnostic sensitivity of 8% (49/591) (p<0.01). Thus, the independence of anti-p53 antibodies from established tumor markers allows the serological detection of additional tumor patients. Kaplan-Meier analysis revealed a trend toward a poorer prognosis in hepatocellular carcinoma and breast cancer patients who were anti-p53 serum positive.
Testing for anti-p53 antibodies can increase diagnostic sensitivity when used in combination with the measurement of conventional tumor markers. This increase is achieved without a parallel decrease in specificity.
However, it can be used for monitoring the response of breast cancer patients to therapy and in detecting recurrent disease (Keyhani et al., 2005).
